[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics,2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
doi: 10.3322/caac.21590
|
[2] |
McCune JS. Rapid advances in immunotherapy to treat cancer[J]. Clin Pharmacol Ther, 2018, 103(4):540-544.
doi: 10.1002/cpt.985
pmid: 29527663
|
[3] |
Thun MJ, DeLancey JO, Center MM, et al. The global burden of cancer:priorities for prevention[J]. Carcinogenesis, 2010, 31(1):100-110.
doi: 10.1093/carcin/bgp263
|
[4] |
Bowles EJA, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment:a retrospective cohort study[J]. J Natl Cancer Inst, 2012, 104(17):1293-1305.
doi: 10.1093/jnci/djs317
|
[5] |
Handy CE, Quispe R, Pinto X, et al. Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment:together we are stronger[J]. Circulation, 2018, 138(7):727-734.
doi: 10.1161/CIRCULATIONAHA.118.035516
|
[6] |
Francis SA, Asnani A, Neilan T, et al. Optimizing cardio-oncology programs for cancer patients[J]. Future Oncol, 2015, 11(14):2011-2015.
doi: 10.2217/fon.15.128
pmid: 26198828
|
[7] |
Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors:a scientific statement from the American heart association[J]. Circulation, 2019, 139(21):e997-e1012.
doi: 10.1161/CIR.0000000000000679
|
[8] |
何虹燕, 李骁, 李真, 等. 《2019美国心脏协会肿瘤心脏病患者心脏康复治疗声明》解读[J]. 中国循环杂志, 2020, 35(10):1036-1040.
|
|
He HY, Li X, Li Z, et al. Interpretation of the 2019 American heart association cardiac rehabilitation statement for cardio-oncology patients[J]. Chin Circ J, 2020, 35(10):1036-1040.
|
[9] |
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2016, 37(36):2768-2801.
doi: 10.1093/eurheartj/ehw211
pmid: 27567406
|
[10] |
Khouri MG, Douglas PS, MacKey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer:addressing the unresolved issues[J]. Circulation, 2012, 126(23):2749-2763.
doi: 10.1161/CIRCULATIONAHA.112.100560
|
[11] |
徐兰, 夏爽, 黎励文. 肿瘤心脏病学:交叉学科的机遇与挑战[J]. 中华心血管病杂志, 2021, 49(2):198-204.
doi: 10.3760/cma.j.cn112148-20200706-00536
pmid: 33611911
|
|
Xu L, Xia S, Li LW. Cardiovascular oncology:opportunities and challenges of interdisciplinarity[J]. Chin J Cardiol, 2021, 49(2):198-204.
doi: 10.3760/cma.j.cn112148-20200706-00536
pmid: 33611911
|
[12] |
国家卫生健康委. 全国护理事业发展规划(2021-2025年)[EB/OL]. (2022-04-29). http://www.gov.cn/zhengce/zhengceku/2022-05/09/content_5689354.htm.
|
[13] |
Armenian SH, Xu LF, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer:a community-based ret-rospective cohort study[J]. J Clin Oncol, 2016, 34(10):1122-1130.
doi: 10.1200/JCO.2015.64.0409
pmid: 26834065
|
[14] |
Li XL, Geng J, Zhao JX, et al. Trimethylamine N-oxide exacerbates cardiac fibrosis via activating the NLRP3 inflammasome[J]. Front Physiol, 2019, 10:866.
doi: 10.3389/fphys.2019.00866
pmid: 31354519
|
[15] |
李小云, 梁敉宁, 黄金, 等. 3 119名护士新型冠状病毒肺炎相关知识现况调查与分析[J]. 中华护理教育, 2020, 17(4):324-327.
|
|
Li XY, Liang MN, Huang J, et al. A survey of the COVID-19 knowledge in 3 119 nurses[J]. Chin J Nurs Educ, 2020, 17(4):324-327.
|
[16] |
Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma[J]. J Clin Oncol, 2007, 25(31):4952-4960.
doi: 10.1200/JCO.2006.08.0499
pmid: 17971593
|
[17] |
Alvarez-Cardona JA, Ray J, Carver J, et al. Cardio-oncology education and training[J]. J Am Coll Cardiol, 2020, 76(19):2267-2281.
doi: 10.1016/j.jacc.2020.08.079
pmid: 33153587
|
[18] |
Momino K, Mitsunori M, Yamashita H, et al. Collaborative care intervention for the perceived care needs of women with breast cancer undergoing adjuvant therapy after surgery:a feasibility study[J]. Jpn J Clin Oncol, 2017, 47(3):213-220.
doi: 10.1093/jjco/hyw189
pmid: 28003321
|